Kalaris Therapeutics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell KLRS and other ETFs, options, and stocks.About KLRS
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases.
KLRS Key Statistics
Stock Snapshot
Kalaris Therapeutics(KLRS) stock is priced at $6.12, giving the company a market capitalization of 140.32M. It carries a P/E multiple of -1.48.
On 2026-03-25, Kalaris Therapeutics(KLRS) stock moved within a range of $5.96 to $6.69. With shares now at $6.12, the stock is trading +2.6% above its intraday low and -8.6% below the session's peak.
Trading volume for Kalaris Therapeutics(KLRS) stock has reached 59.57K, versus its average volume of 56.94K.
The stock's 52-week range extends from a low of $2.14 to a high of $11.88.
The stock's 52-week range extends from a low of $2.14 to a high of $11.88.
KLRS News
New insider activity at Kalaris Therapeutics ( (KLRS) ) has taken place on March 23, 2026. Kalaris Therapeutics’ Chief Accounting Officer, Brett R. Hagen, has...
Analyst ratings
83%
of 6 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.